Skip to content

YPOG advises Aignostics on $34 million Series B financing round

Berlin, October 30, 2024 – YPOG advised global artificial intelligence (AI) company Aignostics on its latest $34 million Series B financing round. The round was led by ATHOS, with investments from the Mayo Clinic and growth financing from HTGF. It also received investments from existing investors including Wellington Partners, Boehringer Ingelheim Venture Fund, CARMA Fund, and the VC Fonds Technologie managed by IBB Ventures. Aignostics has raised more than $55 million to date, demonstrating investor confidence in its unique AI models and well-defined commercial strategy.

Started in 2018, Aignostics was initially founded as a spin-off from Charité and Berlin Institute of Health in 2020. The AI company turns complex multimodal pathology data into transformative insights. 

Following the closing of the latest financing round, Aignostics plans to create new products for biopharmaceutical clients, drive growth in the United States, and develop advanced foundation models for pathology in collaboration with Mayo Clinic. The new funding will enhance Aignostics’ capabilities in target identification, translational research, and companion diagnostics (CDx), while also backing various strategic initiatives. 

“2024 has been a pivotal year for us that has included a major strategic collaboration with Bayer and the launch of our first foundation model, RudolfV,” says Viktor Matyas, CEO and Co-Founder of Aignostics. “With RudolfV, we’ve gained the ability to quickly develop cost-efficient algorithms that generalize to the real-world. Now with this new round of funding, we’re turning our most popular algorithms into products that will help usher in an era of truly generalizable AI for computational pathology.” 


Team

Dr. Martin Schaper (Lead, Corporate/Transactions), Partner, Berlin 
Dr. Jonas von Kalben (Transactions), Senior Associate, Berlin 
Anja Schindler (Transactions), Senior Associate, Berlin 
Benedikt Kreuder (Transactions), Senior Associate, Berlin 
Dr. Jacob Schreiber (Transactions), Senior Associate, München 

 

About Aignostics

Aignostics is an artificial intelligence (AI) company that turns complex multimodal pathology data into transformative insights. By combining proprietary access to multimodal clinical data, industry-leading technologies, and rigorous science, Aignostics develops best-in-class products and services for the next generation of precision medicine. Through collaborations with its biopharma partners, Aignostics supports drug discovery, translational research, clinical trials, and CDx development. Established in 2018, Aignostics is a spin-off from Charité Berlin, one of the world’s largest and most esteemed university hospitals. Aignostics is funded by leading investors and has operations in Berlin and New York.
Further information at
aignostics.com


About us

YPOG stands for You + Partners of Gamechangers – forward-thinking legal and tax advice. Supporting companies that are focused on emerging technologies, YPOG embraces change as an opportunity to develop cutting-edge solutions. The YPOG team offers comprehensive expertise in the areas of Funds, Tax, Transactions, Corporate, Banking, Regulatory + Finance, IP/IT/Data Protection, Litigation, and Corporate Crime + Compliance + Investigations. YPOG is one of the leading law firms in Germany for venture capital, private equity, fund structuring, and the implementation of distributed ledger technology (DLT) in financial services. Both the firm and its partners are regularly recognized by renowned national and international publications such as JUVE, Best Lawyers, Chambers and Partners, Leaders League, and Legal 500. YPOG is home to more than 150 experienced attorneys, tax advisors and tax specialists as well as a notary, working across offices in Berlin, Hamburg, Cologne, and Munich. 

Further information: www.ypog.law/en/ and www.linkedin.com/company/ypog